This content is machine translated Multiple sclerosis therapy Early use of highly effective therapies In recent years, the number of disease-modifying therapies for the treatment of multiple sclerosis has increased dramatically. Increasing data support the early use of highly effective therapies (HRT), which can…
View Post 9 min This content is machine translated The ASCLEPIOS studies Ofatumumab has the potential to be a game changer Prof. Ludwig Kappos, M.D., Basel, Switzerland, together with Prof. Stephen L. Hauser, M.D., Director of the UCSF Weill Institute for Neurosciences, San Francisco, USA, chaired the Steering Committee of the…
View Post 6 min This content is machine translated KESIMPTA® (ofatumumab) for the treatment of relapsing-remitting multiple sclerosis KESIMPTA® (ofatumumab) shows superior efficacy to teriflunomide even in therapy-naïve patients What benefits can patients with relapsing-remitting multiple sclerosis (RMS) expect from first-line treatment with ofatumumab (KESIMPTA®)? The answer to this question was provided by a subgroup analysis of data from…
View Post 6 min This content is machine translated KESIMPTA® (ofatumumab) for the treatment of relapsing-remitting multiple sclerosis High efficacy with good tolerability For patients with relapsing-remitting multiple sclerosis (RMS), KESIMPTA® (ofatumumab) has recently become the first subcutaneous antibody-based therapy option available. In the ASCLEPIOS I and II trials, ofatumumab was shown to…
